| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Rosmariquinone targets the central benzodiazepine receptor, where it acts as a partial agonist with an IC50 of 0.3 μM. It also induces ROS- and p53-dependent apoptosis, indicating involvement in cell death pathways. The compound inhibits carboxylesterase 2 (CES2) with a Ki of 0.04 μM and SARS-CoV main protease (Mpro). It has been shown to inhibit the increase in mRNA abundance of the GABAA receptor α4 subunit induced by ethanol withdrawal. Rosmariquinone also exhibits antileukemic activity by inducing mitochondrial dysfunction.
|
|---|---|
| ln Vitro |
In vitro, Rosmariquinone acts as a partial agonist at the central benzodiazepine receptor with an IC50 of 0.3 μM. It induces ROS- and p53-dependent apoptosis in colon cancer cells, inhibits P-glycoprotein and cell growth in doxorubicin-resistant HepG2 cells, and exhibits antileukemic activity by inducing mitochondrial dysfunction. The compound inhibits carboxylesterase 2 with a Ki of 0.04 μM and shows activity against SARS-CoV main protease. These diverse activities highlight its multi-target pharmacological potential.
|
| ln Vivo |
Specific in vivo data for Rosmariquinone are limited, but the compound is described as orally active, suggesting systemic bioavailability following oral administration. Given its benzodiazepine receptor partial agonist activity, the compound may have potential for in vivo studies in anxiety, seizure, or sedation models. Its anticancer activity could be evaluated in xenograft models, and its CES2 inhibitory activity may have implications for drug-drug interaction studies. Ethanol withdrawal models have been used to study its effects on GABAA receptor expression. The compound's antiviral activity against SARS-CoV could be evaluated in appropriate in vivo infection models.
|
| Enzyme Assay |
The benzodiazepine receptor binding assay is performed using radioligand binding techniques. Membrane preparations from rat brain or cells expressing recombinant benzodiazepine receptors are incubated with a radiolabeled benzodiazepine ligand (e.g., [³H]flunitrazepam) and various concentrations of Rosmariquinone. Specific binding is determined by subtracting non-specific binding (in the presence of excess unlabeled ligand). IC50 values are calculated from competition binding curves. CES2 inhibitory activity is assessed using fluorometric or chromatographic assays with appropriate substrates.
|
| Cell Assay |
For apoptosis studies, cancer cell lines such as colon cancer cells or HepG2 cells are cultured in appropriate media. Cells are treated with Rosmariquinone at various concentrations for 24-72 hours. Apoptosis is assessed by measuring caspase-3/7 activity, Annexin V staining, or DNA fragmentation. ROS production is measured using fluorescent probes such as DCFH-DA. P-glycoprotein inhibition is assessed in doxorubicin-resistant cells by measuring intracellular doxorubicin accumulation via flow cytometry. Cell viability is measured using MTT or CellTiter-Glo assays.
|
| Animal Protocol |
In vivo studies for Rosmariquinone would be conducted in appropriate animal models depending on the research focus. For anticancer activity, xenograft models using cancer cell lines would be employed, with oral administration of the compound and tumor volume measurement as the primary endpoint. For neuropharmacological studies, behavioral tests such as the elevated plus maze, open field test, or pentylenetetrazole-induced seizure model would be used to evaluate benzodiazepine receptor-mediated effects. Ethanol withdrawal models would assess the compound's effects on GABAA receptor expression.
|
| ADME/Pharmacokinetics |
S pecific pharmacokinetic data for Rosmariquinone are not extensively reported. The compound is described as orally active, indicating reasonable oral absorption and bioavailability. As a diterpenoid with moderate lipophilicity, it is expected to distribute to tissues including the brain, consistent with its central benzodiazepine receptor activity. Formal PK studies would be required to determine parameters such as half-life, clearance, volume of distribution, and oral bioavailability in animal models.
|
| Toxicity/Toxicokinetics |
Toxicological data for Rosmariquinone are limited. As a natural product from Salvia miltiorrhiza, which has a long history of use in traditional medicine, the compound is generally considered to have a moderate safety profile at the concentrations used in research. However, comprehensive toxicology studies including acute and repeated-dose toxicity assessments have not been reported. The compound's effects on the central nervous system via benzodiazepine receptor modulation warrant careful evaluation for potential sedative or other CNS-related effects.
|
| References | |
| Additional Infomation |
Miltirone is an abiran diterpenoid compound. It has been reported to exist in Salvia miltiorrhiza, medicinal Salvia miltiorrhiza, and other organisms with relevant data.
Rosmariquinone (Miltirone) is a natural diterpenoid from Salvia miltiorrhiza that acts as a central benzodiazepine receptor partial agonist (IC50 = 0.3 μM) and induces ROS- and p53-dependent apoptosis. It inhibits CES2 (Ki = 0.04 μM) and SARS-CoV Mpro. Orally active, it is used in cancer and neuropharmacology research. No clinical trials or approvals exist. For research use only. |
| Molecular Formula |
C19H22O2
|
|---|---|
| Molecular Weight |
282.3768
|
| Exact Mass |
282.161
|
| CAS # |
27210-57-7
|
| PubChem CID |
160142
|
| Appearance |
Orange to red solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
421.6±45.0 °C at 760 mmHg
|
| Melting Point |
98-100℃ (hexane )
|
| Flash Point |
179.4±14.4 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.556
|
| LogP |
5.67
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
21
|
| Complexity |
498
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
FEFAIBOZOKSLJR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H22O2/c1-11(2)14-10-12-7-8-15-13(6-5-9-19(15,3)4)16(12)18(21)17(14)20/h7-8,10-11H,5-6,9H2,1-4H3
|
| Chemical Name |
8,8-dimethyl-2-propan-2-yl-6,7-dihydro-5H-phenanthrene-3,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~177.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.85 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (8.85 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5413 mL | 17.7066 mL | 35.4133 mL | |
| 5 mM | 0.7083 mL | 3.5413 mL | 7.0827 mL | |
| 10 mM | 0.3541 mL | 1.7707 mL | 3.5413 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
